This episode of Immune delves into the immunology of the nasal cavity, discussing two recent papers published in Nature. The first paper, presented by Brienne Barker, investigates the cause of chronic inflammatory nasal polyps. It identifies a specific subset of CD8+ T cells that express granzyme K as the key drivers of the disease. These cells promote inflammation by unconventionally activating the complement cascade, suggesting that inhibiting granzyme K could be a novel therapeutic strategy for airway inflammatory diseases.
The second paper, presented by Steph Langel, explores the origins of protective IgA-producing B cells in the nose. Using sophisticated mouse models with fluorescent reporters, the study traces how these B cells are first activated by commensal microbes or vaccines in the Nasal-Associated Lymphoid Tissues (NALT). They then mature in germinal centers, class-switch to IgA, and migrate to the nasal turbinates to secrete antibodies. The discussion highlights how this fundamental research confirms classical immunological pathways in the nose and provides a mechanistic basis for developing more effective intranasal vaccines.
The Immunology of the Nose: From Inflammation to Protection
3:07 The Cause of Nasal Polyps: Brienne introduces a study on recurrent airway inflammatory diseases, specifically focusing on what drives chronic nasal polyps. Researchers found that persistent clones of CD8+ T cells were involved.
10:13 A New Culprit: Granzyme K: The study identified that these pathogenic CD8+ T cells uniquely expressed high levels of a protease called granzyme K. Levels of this enzyme were a better predictive biomarker for disease severity than traditional markers associated with allergic inflammation.
12:24 Linking T-Cells to Complement: In a key finding, the researchers discovered that granzyme K directly activates the complement system, an innate immune cascade. This reveals an unexpected mechanism where adaptive T-cells can directly fuel tissue inflammation.
17:55 A Potential Therapeutic Target: Experiments in mouse models showed that both genetically removing and pharmacologically inhibiting granzyme K significantly reduced airway inflammation, highlighting it as a promising new target for treating diseases like asthma and rhinitis.
25:48 Where Do Nasal IgA Antibodies Come From?: Steph discusses a second paper that investigates the origin of IgA-producing B cells that protect the nose. The study focuses on the Nasal-Associated Lymphoid Tissues (NALT).
31:12 Advanced Mouse Models to Trace Cells: The study used elegant mouse models that fluorescently label B cells as they become activated in germinal centers, allowing researchers to track their development and migration in real-time.
36:41 Commensal Microbes Drive Baseline Immunity: The NALT contains robust, pre-existing germinal centers that are active even without infection, stimulated by the nose's natural commensal microbiome. This baseline activity is critical for nasal immunity.
43:04 Tracing the Immune Response to a Nasal Vaccine: After an intranasal vaccination, antigen-specific B and T cells were shown to interact and activate in specific zones within the NALT before maturing into IgA-producing cells.
58:10 Homing to the Nasal Turbinates: After maturing in the NALT (the inductive site), the IgA-secreting plasma cells migrate to the nasal turbinates (the effector site) to release antibodies into the nasal cavity. This trafficking is guided by specific molecular signals (CCR10 and CCL28).
1:05:07 Implications for Nasal Vaccines: The hosts discuss how this work confirms the fundamental mechanics of a mucosal immune response in the nose. Understanding these cellular pathways is critical for overcoming challenges in developing durable and effective intranasal vaccines.